‘Switching between AD drugs’ discussed at NA audit
By Whang, byung-woo | translator Alice Kang
24.10.11 05:46:34
가나다라
0
Representative Jin-Suk Jeon of the Democratic Party of Korea inquires about severe atopic dermatitis treatments
Relvant societies voice support for swiching between ‘biologics’ - JAK inhibitors’ for moderate-to-severe atopic dermatitis'
Minister of Health and Welfare Kyoo-Hong Cho, ‘I understand that switching between drugs for atopic dermatitis is an important issue, and I think the evidence is accumulating now. I was told that the Health Insurance Review and Assessment Service wi
The issue of switching between medications for severe atopic dermatitis, whose need had been voiced constantly in the clinical field, has been mentioned during the National Assembly Audit, attracting attention to whether the reimbursement environment will change.
▲ (Clockwise from top left) Pic of Dupixent, RInvoq, Olumiant, Adtralza, Civinqo
During the National Audit of the National Assembly's Health and Welfare Committee on the 8th of this month, Democratic Party Rep Jin-Suk Jeon asked Minister of Health and Welfare Kyoo-Hong Cho about the issue of switching between medication for atopic dermatitis.
Currently, the special calculation and reimbursement standards for switching between medications in severe atopic dermatitis stipulate that ‘starting treatment
Whang, byung-woo(tuai@dailypharm.com)
If you want to see the full article, please JOIN US (click)